Site-blocking antisense oligonucleotides as a mechanism to fine-tune MeCP2 expression
RNA · 2024
DOI: 10.1261/rna.080220.124 ↗Kurz gefasst
Fachartikel in der Zeitschrift RNA, 2024. Verfasst von Amanda M Vanderplow und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Pharmacology and Neuroscience, Loyola University Chicago, Maywood, Illinois 60153, USA. Hauptthemen laut MEDLINE: Methyl-CpG-Binding Protein 2, Oligonucleotides, Antisense, 3' Untranslated Regions, MicroRNAs. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NICHD NIH HHS.
Abstract (Originalsprache)
Rett syndrome (RTT) is a neurodevelopmental disorder caused by loss-of-function mutations in the methyl-CpG-binding protein 2 ( MECP2 ) gene. Despite its severe phenotypes, studies in mouse models suggest that restoring MeCP2 levels can reverse RTT symptomology. Nevertheless, traditional gene therapy approaches are hindered by MeCP2's narrow therapeutic window, complicating the safe delivery of viral constructs without overshooting the threshold for toxicity. The 3′ untranslated region (3′ UTR) plays a key role in gene regulation, where factors like miRNAs bind to pre-mRNA and fine-tune expression. Given that each miRNA's contribution is modest, blocking miRNA binding may represent a potential therapeutic strategy for diseases with high dosage sensitivity, like RTT. Here, we present a series of site-blocking antisense oligonucleotides (sbASOs) designed to outcompete repressive miRNA binding at the MECP2 3′ UTR. This strategy aims to increase MeCP2 levels in patients with missense or late-truncating mutations, where the hypomorphic nature of the protein can be offset by enhanced abundance. Our results demonstrate that sbASOs can elevate MeCP2 levels in a dose-dependent manner in SH-SY5Y and patient fibroblast cell lines, plateauing at levels projected to be safe. Confirming in vivo functionality, sbASO administration in wild-type mice led to significant Mecp2 upregulation and the emergence of phenotypes associated with Mecp2 overexpression. In a T158M neural stem cell model of RTT, sbASO treatment significantly increased MeCP2 expression and levels of the downstream effector protein brain-derived neurotrophic factor (BDNF). These findings highlight the potential of sbASO-based therapies for MeCP2-related disorders and advocate for their continued development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Pharmacology and Neuroscience, Loyola University Chicago, Maywood, Illinois 60153, USA.
- Department of Pharmacology, University of Michigan, Ann Arbor, Michigan 48109, USA.
- Department of Molecular Pharmacology and Neuroscience, Loyola University Chicago, Maywood, Illinois 60153, USA rgogliotti@luc.edu.
Förderung
- NINDS NIH HHS
- NICHD NIH HHS
Zitieren
APA
Vanderplow, A. M., Dodis, G. E., Rhee, Y., Cikowski, J. J., Gonzalez, S., Smith, M. L., & Gogliotti, R. G. (2024). Site-blocking antisense oligonucleotides as a mechanism to fine-tune MeCP2 expression. RNA. https://doi.org/10.1261/rna.080220.124
Vancouver
Vanderplow AM, Dodis GE, Rhee Y, Cikowski JJ, Gonzalez S, Smith ML, et al. Site-blocking antisense oligonucleotides as a mechanism to fine-tune MeCP2 expression. RNA. 2024. doi:10.1261/rna.080220.124
BibTeX
@article{Vanderplow2024,
author = {Vanderplow, Amanda M and Dodis, Grace E and Rhee, Yewon and Cikowski, Jakub J and Gonzalez, Sonia and Smith, Mackenzie L and Gogliotti, Rocco G},
title = {Site-blocking antisense oligonucleotides as a mechanism to fine-tune MeCP2 expression},
journal = {RNA},
year = {2024},
doi = {10.1261/rna.080220.124}
}
EUVIMED